<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30008">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716051</url>
  </required_header>
  <id_info>
    <org_study_id>I15037/WILSON</org_study_id>
    <nct_id>NCT02716051</nct_id>
  </id_info>
  <brief_title>Wholebody MRI In Lung Cancer StagiNg</brief_title>
  <acronym>WISLON</acronym>
  <official_title>Initial Staging of Bronchopulmonary Neoplasia: Whole-body MRI Versus Pet Scanner</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic Resonnace Imaging (MRI) and Positron Emission Tomography (PET) can be both used in
      detection of nodes in patients with cell lung cancer (NSCLC).

      However, the cardiorespiratory synchronization in the MRI, allowing acquisition of
      synchronous images with breathing and heart movements should increase the sensitivity of
      detection of pathologic mediastinal lymph nodes.

      Given its high sensitivity, whole-body MRI with diffusion could possibly be at least as
      informative as PET, while being less expensive, not radiant.

      The purpose of this study is to evaluate the performance of whole-body MRI with diffusion
      with cardiorespiratory synchronization, on the detection of mediastinal nodes (which are
      known to be less well detected by MRI) compared to PET.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Th consistency of the locations of mediastinal lesions</measure>
    <time_frame>Day 1</time_frame>
    <description>Node localization according to MRI and PET scan measurements on the same day</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At day 1 , in the morning, patient will undergo an PET analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Whole body MRI with cardiac and pulmonary synchronization</description>
    <arm_group_label>MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET</intervention_name>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years,

          -  Neoplasia bronchopulmonary (SCLC and NSCLC) newly diagnosed,

          -  Patient potentially eligible for curative treatment, but no no treatment started,

          -  Patients for whom a PET scan and MRI are planned

        Non Inclusion Criteria:

          -  claustrophobia,

          -  Implantable Medical Device

          -  not compatible pacemaker type or heart valve, metal splinters eye)

          -  Pregnant or lactating women,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvain Martin, MD</last_name>
    <phone>0555052073</phone>
    <email>sylvain.martin@chu-limoges.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain Martin, MD</last_name>
      <email>sylvain.martin@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 16, 2016</lastchanged_date>
  <firstreceived_date>March 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
